<table width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 4 Other Potentially Significant Drug Interactions</caption>
<col align="left" span="1" valign="top" width="40%"></col>
<col align="left" span="1" valign="top" width="30%"></col>
<col align="left" span="1" valign="top" width="30%"></col>
<tbody>
<tr>
<th colspan="1">Concomitant Drug Class or Food</th>
<th colspan="1">Noted or anticipated Outcome</th>
<th colspan="1">Clinical Comment</th>
</tr>
<tr>
<td>
<content stylecode="bold">HMG-Co A Reductase Inhibitors:</content>
<br/>atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin</td>
<td>Pharmacokinetic and/or pharmacodynamic interaction: the addition of one drug to a stable long-term regimen of the other has resulted in myopathy and rhabdomyolysis (including a fatality)</td>
<td>Weigh the potential benefits and risks and carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during initial therapy; monitoring CPK (creatine phosphokinase) will not necessarily prevent the occurrence of severe myopathy.</td>
</tr>
<tr>
<td>
<content stylecode="bold">Other Lipid Lowering Drugs</content>:  										<br/>fibrates, gemfibrozil</td>
</tr>
<tr>
<td>
<content stylecode="bold">Digitalis Glycosides:</content>
<br/>digoxin</td>
<td>P-gp substrate; rhabdomyolysis has been reported</td>
</tr>
</tbody>
</table>